Skip to content

SAVE Studie- SArcoma Surgery With Vacuum Enhanced Wound Treatment Randomised Study to Evaluate the Wound Management in Sarcoma Surgery

SAVE Studie- SArcoma Surgery With Vacuum Enhanced Wound Treatment Randomised Controlled Study to Evaluate the Wound Management in Sarcoma Surgery

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06889532
Acronym
SAVE
Enrollment
100
Registered
2025-03-21
Start date
2024-11-01
Completion date
2025-12-31
Last updated
2025-03-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Soft Tissue Sarcoma (STS)

Keywords

randomized, controlled, vacuum therapy, sarcoma, soft tissue sarcoma

Brief summary

The aim of this study is to evaluate local complications following sarcoma resection in the groin and thigh regions with regard to the planned wound closure method. To this end, temporary soft tissue coverage using a vacuum-assisted closure (VAC) system and delayed secondary closure with wound sutures and drainage placement will be compared to primary closure with drainage in terms of wound infections, revisions, and seroma formation.

Detailed description

The study, SAVE Study - SArcoma Surgery with Vacuum Enhanced Wound Treatment, is a prospective, ran-domized, controlled clinical trial aimed at comparing the effectiveness of two surgical approaches to optimize wound care following sarcoma resections. The study is designed as a multicenter trial. The study includes two arms: * Intervention Group: In this group, a vacuum-assisted closure (VAC) system is applied intraoperatively to seal the wound, followed by a secondary closure after 3-7 days. * Control Group: In this group, wound closure is performed using primary sutures or staples, combined with the placement of a subcutaneous Redon drainage system. The planned study start date is November 1, 2024. Before enrolling patients, all participating centers must have received approval from their ethics committees. Initially, potential participants will be assessed for eligibility based on the inclusion and exclusion criteria. They will be educated about the study and provided with a standardized information sheet across all centers. After consent, they will be enrolled in the study. Next, patients will be randomly assigned to one of the study groups (Intervention group or Control group). This will be done through computer-assisted randomization to ensure the assignment is both random and balanced. The randomization process will be completed intraoperative after assessing the wound cavity (both wound clo-sures should be feasible). The surgical care should be performed by a certified sarcoma surgeon. The guidelines for surgical techniques are as follows: The incision and resection should follow the surgical standards of the respective center. * Careful attention should be given to thorough hemostasis after resection. * In the intervention group, a vacuum-assisted closure (VAC) system will be used for wound closure. The VAC system should be applied with a suction pressure of -125mmHg to -75 mmHg. In cases where there is a Vac on vessel situation, the suction pressure can be reduced to -25 mmHg. \- The control group will receive primary wound closure via either a single-button suture, continuous su-ture, or staple closure, depending on the center's standard. Drainages should be placed regularly after primary wound closure. * For the VAC group, the timing of secondary closure is at the discretion of the surgeon. However, the VAC dressing should not remain in place for more than 7 days. * Secondary wound closure can be performed using a single-button suture, continuous suture, or stapling. A suction drainage should be placed also after secondary wound closure. A minimum of 50 patients per study arm will be recruited, resulting in a total of at least 100 participants. All patients undergoing sarcoma surgery at participating sarcoma centers between November 2024 and December 2025 will be screened for inclusion in the study. 1. Inclusion Criteria: Patients undergoing resection of soft tissue sarcomas in the lower extremity and groin regions are eligible for inclusion if the following criteria are met: * Patients must be over 18 years old. * Patients of any gender and background can be included. * The largest tumor diameter on imaging must be at least 5 cm. Preoperative imaging is required to assess tumor dimensions. * Sarcomas must be located in the lower extremity or groin. * Cases must be discussed preoperatively at an interdisciplinary tumor board. * Patients must provide informed consent to participate in the study. 2. Exclusion Criteria: Patients meeting any of the following conditions will be excluded: * Tumors smaller than 5 cm and superficial masses. * Patients with local recurrences or prior wound healing complications in the surgical area. * Patients with ulcerating or infected tumors, or those requiring emergency surgery. * Other Soft Tissue Tumors such as Kaposi sarcoma. * for whom direct closure is not possible during the initial surgery due to the extent of resection.

Interventions

PROCEDUREIntervention Group: In this group, a vacuum-assisted closure (VAC) system is applied intraoperatively to seal the wound, followed by a secondary closure after 3-7 days.

Intervention Group: In this group, a vacuum-assisted closure (VAC) system is applied intraoperatively to seal the wound, followed by a secondary closure after 3-7 days.

Sponsors

Maastricht University Medical Center
CollaboratorOTHER
University Hospital, Basel, Switzerland
CollaboratorOTHER
University Hospital Erlangen
CollaboratorOTHER
Universitätsmedizin Mannheim
CollaboratorOTHER
Universitätsklinikum Hamburg-Eppendorf
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Intervention model description

The study, SAVE Study - SArcoma Surgery with Vacuum Enhanced Wound Treatment, is a prospective, ran-domized, controlled clinical trial aimed at comparing the effectiveness of two surgical approaches to optimize wound care following sarcoma resections. The study is designed as a multicenter trial. The study includes two arms: * Intervention Group: In this group, a vacuum-assisted closure (VAC) system is applied intraoperatively to seal the wound, followed by a secondary closure after 3-7 days. * Control Group: In this group, wound closure is performed using primary sutures or staples, combined with the placement of a subcutaneous Redon drainage system.

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

Patients must be over 18 years old. * Patients of any gender and background can be included. * The largest tumor diameter on imaging must be at least 5 cm. Preoperative imaging is required to assess tumor dimensions. * Sarcomas must be located in the lower extremity or groin. * Cases must be discussed preoperatively at an interdisciplinary tumor board. * Patients must provide informed consent to participate in the study.

Exclusion criteria

* Tumors smaller than 5 cm and superficial masses. * Patients with local recurrences or prior wound healing complications in the surgical area. * Patients with ulcerating or infected tumors, or those requiring emergency surgery. * Other Soft Tissue Tumors such as Kaposi sarcoma. * for whom direct closure is not possible during the initial surgery due to the extent of resection.

Design outcomes

Primary

MeasureTime frameDescription
Lymphatic fistula3 MonthsLymphatic fistula or Drainage secretion of \>50ml/24h after 5 postoperative days
Wound Infection3 Months
Wound Seroma3 MonthsSeroma in Wound
Wound complication3 MonthsThe primary objective of the study is to compare wound complications after vacuum therapy versus direct closure.
Wound Dehiscence3 MonthsWound dehiscence
Revision Surgery or conservative treatment3 MonthsIf Revision surgery or antibiotic treatment is required due to a wound infection.

Secondary

MeasureTime frameDescription
Risk factors for wound complications3 MonthsIn addition, the benefit of using drainage to prevent wound infections will be evaluated. For this, the type of drainage, the location of the drainage, the volume of secretion, and the duration of the drainage will be docu-mented. The impact of different sarcoma entities on the occurrence of wound infections will also be investi-gated. The effects of BMI, age, smoking, and pre-existing conditions such as diabetes mellitus, cardiovascular diseases, and immunosuppression will be assessed. A subgroup analysis will be performed to evaluate the relevance of neoadjuvant treatment. Furthermore, the influence of factors such as tumor location (differences between groin, thigh, and lower leg) and actual tumor size (differences between 5-10 cm and \>10 cm) will be examined.

Countries

Germany

Contacts

Primary ContactSimone Dr. med. Schewe
s.schewe@uke.de015222841914

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026